REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
 
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Cyclopeptides > 12 To 15 Peptide Repeating Units In Known Peptide Chain 12 To 15 Peptide Repeating Units In Known Peptide Chain12 To 15 Peptide Repeating Units In Known Peptide Chain patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027090 - Methods of treating cognitive dysfunction by modulating brain energy metabolism Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed. ... 02/01/07 - 20070027089 - Inhibitors of amyloid precursor protein processing Disclosed is a method of using a compound as an inhibitor for β-secretase, wherein the compound is capable of binding to the site within the β-secretase recognition and/or cleavage site on amyloid precursor protein to specifically inhibit the β-secretase's activity to cleave amyloid precursor protein with maintaining its activities to ... 02/01/07 - 20070027088 - Peptides and mimetics for reducing symptoms of toxic shock syndrome and septic shock This invention relates to compositions and methods for providing protection against, or reducing the severity of, toxic shock syndrome, septic shock, food poisoning, and autoimmune diseases which are associated with toxin producing bacteria. This invention also relates to methods of using peptides, derivatives, mimetics, and antibodies for the prevention and ... 01/25/07 - 20070021345 - Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such ... 01/18/07 - 20070015712 - Antimicrobial theta defensins, analogs thereof, and methods of use The invention provides theta defensin analogs having antimicrobial activity. The invention also provides a method of reducing or inhibiting growth or survival of a microorganism in an environment capable of sustaining the growth or survival of the microorganism, comprising administering an effective amount of a theta defensin analog to the ... 01/04/07 - 20070004632 - Peptides Peptides from cancer related protein products of frameshift mutated genes which eliciting T cellular immunity for use in cancer vaccines and compositions for anticancer treatment. ... 12/28/06 - 20060293242 - Transporting of taxoid derivatives through the blood brain barrier Taxoid derivatives are used in the treatment of cancers, particular cancers of the central nervous system, such as brain cancers. Taxoid derivatives are transported across the blood/brain barrier (BBB). A compound is provided which consists of at least one taxoid derivative bound to at least one vector peptide capable of ... 12/21/06 - 20060287240 - Method of stimulating prosaposin receptor activity A method for stimulating prosaposin receptor activity in a cell by transfecting the cell with a DNA or RNA molecule encoding prosaposin or a prosaposin receptor agonist. The DNA or RNA molecule is administered either in vivo or used to transfect neural cells or neural stem cells ex vivo followed ... 12/21/06 - 20060287239 - Biologically active peptides Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced thereform are also disclosed. ... 12/14/06 - 20060281683 - Branched cationic copolymers and methods for antimicrobial use The invention provides a branched copolymer for the treatment of bacterial, fungal, and viral infections. The branched copolymer is characterized as having (i) at least 10 amino acids, (ii) at least 10% of the amino acids are histidine, (iii) at least 10% of the amino acids are non-histidine, (iv) said ... 12/07/06 - 20060276401 - Polypeptides useful for appetite suppression The present invention relates to polypeptides obtained from bear derivative isolate which are useful in suppressing appetite. The polypeptides of the present invention are most preferably between 12 and 13 amino acid residues in length and a mass of about 1249. The present invention also relates to a method of ... 11/23/06 - 20060264378 - Cxcr4 antagonist and use thereof The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt. ... 11/16/06 - 20060258594 - Methods and compositions for impairing multiplication of hiv-1 A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more ... 11/16/06 - 20060258593 - Methods and compositions for the treatment of gastrointestinal disorders The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction ... 11/02/06 - 20060247176 - Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins and the salts, esters, amides, and acyl forms thereof. Each position represented by a letter indicates a single amino acid residue: B is a basic of polar/large amino acid or a modified form thereof; X is a small or hydrophobic amino acid or a modified form thereof; X* is a ... 10/12/06 - 20060229250 - Ghrelin associated peptide and its uses The invention relates to polypeptides referred to herein as obestatin. Obestatin, analogs and mimetics thereof act in signaling pathways, and are shown to modulate hypertension and other cardiovascular parameters, and gastric emptying. ... 09/14/06 - 20060205666 - Gamma-secretase inhibitors Disclosed, as a γ-secretase inhibitor, is a compound consisting of an amino acid sequence which consists of at least three consecutive amino acids of the amino acid sequence Val-Val-Ile-Ala-Thr-Val-Ile-Val-Ile-Thr-Leu-Val-Met-Leu-Lys-Lys including Leu at position 11, wherein, between the Leu and one or both amino acids located immediately before or after it, ... 07/27/06 - 20060166889 - Insulin conjugates and methods of use thereof The invention relates generally to chimeric peptides and compositions that facilitate the transport of insulin across biological membranes, methods for preparing the chimeric peptides, and a method for treating a subject suffering from diabetes. ... 07/20/06 - 20060160742 - Neuropeptide-2 receptor (y-2r) agonists and uses thereof as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity. ... 07/06/06 - 20060148715 - Structural requirements for stat3 binding and recruitment to phosphotyrosine ligands Inhibitors of Stat3 are disclosed, including small molecules and peptide mimetic inhibitors. Specific Stat3 inhibitors of the invention are useful as beta-turn mimetics. Also disclosed are pharmaceutical compositions of the Stat3 inhibitors of the invention, and methods for using the compounds of the invention to inhibit growth of a cell ... 07/06/06 - 20060148714 - Therapeutic peptide-based constructs The present invention relates generally to small peptide-based constructs, including derivatized constructs, and their therapeutic uses. The sequences of these constructs are based on a reverse subsequence derived from Domain II of bactericidal/permeability-increasing protein (BPI). ... 06/29/06 - 20060142201 - Novel x-conotoxin peptides (-1) An isolated, synthetic or recombinant χ-conotoxin peptide comprising the following sequence of amino acids: Xaa1 Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3 where Xaa1 is a N-terminal Xaa1 is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is ... 06/22/06 - 20060135431 - Peptides and related molecules that bind to tall-1 wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, ... 06/08/06 - 20060122120 - Method of reducing the effects of abeta and compositions therefore The invention provides methods and materials related to inhibiting the effects of Aβ such as neuronal cell death and tau phosphorylation. For example, the invention provides polypeptides, compositions containing polypeptides, transgenic animals, and methods for preventing an Aβ effect (e.g., neuronal cell death in a mammal). ... 06/08/06 - 20060122119 - Peptides for use in antitumor immunotherapy The invention concerns the use of immunogenic peptides representing T epitopes presented by the MHC I, derived from Melan-A, MAGE-A6, gp 100, tyrosinase and NY-ESO-1 antigens for the diagnosis or treatment of melanomas in HLA-B35 subjects. ... 05/25/06 - 20060111299 - Compositions and methods for treating atherosclerosis Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis ... 04/20/06 - 20060084608 - Binding polypeptides and methods based thereon Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or ... 04/06/06 - 20060074026 - Therapeutic agents and methods for cardiovascular disease The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at ... 01/26/06 - 20060019902 - Pth-like peptides The present invention relates to peptides that are parathyroid hormone (PTH) analogs, useful for the treatment of hypoparathyroidism and diseases characterized by bone mass reduction, such as osteoporosis, and for stimulating bone repair or favoring the engraftment of a bone implant; to the pharmaceutical compositions comprising these PTH-like peptides and ... 01/26/06 - 20060019901 - Compositions and methods for counteracting effects of reactive oxygen species and free radicals Peptide compounds and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The peptide compounds may be used to treat or prevent diseases and conditions characterized by ... 01/05/06 - 20060003940 - T-cell death-inducing epitopes Cell death-inducing epitopes and polypeptides containing same. Also disclosed are compounds for inducing death of activated T-cells, a method of producing antibodies to the epitopes, a method of identifying compounds that bind to the epitopes, a method of inducing death of activated T-cells, and pharmaceutical compositions containing the compounds. ... 12/22/05 - 20050282755 - Compositions having antimicrobial activity and uses thereof Provided are compositions and methods useful for reducing microbial populations on and/or in skin, reducing skin inflammation, targeting skin substructures and components, and treating skin conditions such as acne. A composition often comprises an antimicrobial peptidyl moiety having an amino acid sequence conforming to a sequence motif provided herein, and ... 12/08/05 - 20050272661 - Neo-tryptophan The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and ... 11/03/05 - 20050245454 - Methods and compositions for impairing multiplication of hiv-1 A composition which elicits antibodies to multiple known variants of Tat protein of HIV-1 of both the B and non-B clades contains the peptide R1-Asp-Pro-Asn-Leu-Asp-Pro-Trp-Asn-R2 SEQ ID NO: 23, and preferably an additional at least two variants of a peptide or polypeptide of the formula: R1-Asp-Pro-Y7-Leu-X9-Pro-Trp-Z12-R2 (SEQ ID NO: 8). ... 11/03/05 - 20050245453 - Peptides derived from cadherin and methods of use thereof The present invention provides polypeptides and peptides derived from cadherin. The polypeptides and peptides are useful in a method of inhibiting amyloid deposition and a method of inhibiting tumor metastasis. A method of determining susceptibility to Alzheimer's disease and a method of screening for agents that modify cadherin processing are ... 10/13/05 - 20050227924 - Peyer's patch and/or m-cell targeting ligands Purified synthetic polypeptide ligands for targeting pharmaceutical agents and carriers comprising such agents to intestinal epithelial tissue, especially Peyer's patch and/or M-Cell tissue. Also methods of using the ligands. ... 10/06/05 - 20050222038 - Protection against ischemia and reperfusion injury A compound and method for using the compound to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound, either Deltorphin A and/or Dermorphin H, may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function ... 10/06/05 - 20050222037 - Compounds and methods for modulating ve-cadherin-mediated function Compositions and methods for modulating VE-cadherin-mediated functions are provided. The compositions and methods employ VE-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to a VE-cadherin cell adhesion recognition sequence; (b) a non-peptide mimetic of a VE-cadherin cell adhesion ... 10/06/05 - 20050222036 - Peptide compositions with effects on blood glucose The present invention provides compositions and methods for ameliorating neurological or memory disorders and improving learning and cognition through the increase of cyclic AMP. Gilatides, peptides comprising the nine amino acid sequence (SEQ ID NO:1), and functional analogs thereof are disclosed to modulate neurological activity when administered to a subject. ... 09/29/05 - 20050215482 - Compounds and methods for modulating ob-cadherin-mediated function Compositions and methods for modulating OB-cadherin-mediated functions are provided. The compositions and methods employ OB-cadherin modulating agents which generally comprise one or more of: (a) a peptide sequence that is at least 50% identical to an OB-cadherin CAR sequence; (b) a non-peptide mimetic of an OB-cadherin CAR sequence; (c) a ... 09/29/05 - 20050215481 - Antimicrobial peptide, its analogs and antimicrobial composition comprising them Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms. ... 09/29/05 - 20050215480 - Alpha conotoxin peptides with analgesic properties This invention relates to novel α-conotoxin-like peptides comprising the following sequence of amino acids: Xaa1CCSXaa2Xaa3Xaa4CXaa5Xaa6Xaa7Xaa8Xaa9Xaa10Xaa11C—NH2 in which Xaa1 is G or D; Xaa3 is proline, hydroxyproline or glutamine; each of Xaa2 to Xaa8 and Xaa11 is independently any amino acid; Xaa9 is proline, hydroxyproline or glutamine; Xaa10 is aspartate, glutamate ... 09/29/05 - 20050215479 - Diagnostic indicator of thymic function The present disclosure provides a method for determining whether a patient's immune system can be modified through stimulation of thymus function. In one embodiment, sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. In particular, the level of these factors in the patient's ... 09/22/05 - 20050209159 - Effectors of dipeptidyl peptidase iv for topical use wherein A is an amino acid having at least one functional group in the side chain; B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino ... 09/22/05 - 20050209158 - Peptides that bind to hsp90 proteins YSLPGYMVKKLLGA (SEQ ID NO:1) and its active analogs, compositions, and methods of use. ... 08/25/05 - 20050187161 - Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive aspergillosis The present invention concerns novel methods of identifying peptide sequences that selectively bind to fungal surface molecules. The general method, Biopanning and Rapid Analysis of Selective Interactive Ligands (BRASIL) provides for rapid and efficient separation of phage that bind to fungal surface molecules. BRASIL may be used in a pre-selection ... 07/28/05 - 20050164945 - Endotheliase-1 ligands The disclosure describes compounds that can include a peptide or Kunitz domain that binds endotheliase 1 (ET1). The compounds can be used, e.g., to reduce angiogenesis in a subject having or at risk for a neoplastic disorder, modulate the activity of an ET1-expressing cell, modulate proteolysis of a biological structure, ... 07/28/05 - 20050164944 - Synthetic compounds and compositions with enhanced cell binding Compositions of the invention include composites comprising a biomaterial having compounds thereon with enhanced cell binding with respect to collagen. These composites are useful for soft and hard tissue repair or reconstruction and for in vitro uses. Suitable compounds with enhanced cell binding include synthetic peptides that mimic the conformation ... 07/28/05 - 20050164943 - Tumor suppressor gene polypeptides and related nucleic acids, host cells, compositions, and methods of use in inhibition of cell growth, modulation of gene expression, and enhancement of immune-response inducing effect of a vaccine A polypeptide consisting essentially of the amino acid sequence NCEHFVTYCRYG (SEQ ID NO: 1), ENCEHFVNELRYG (SEQ ID NO: 2), NCEHFVNELRYG (SEQ ID NO: 3), RNCEHFVAQLRYG (SEQ ID NO: 4), NCEHFVAQLRYG (SEQ ID NO: 5), or NCEHFVTYLRYG (SEQ ID: 6), or a variant of any of the foregoing, a composition comprising ... 06/30/05 - 20050143310 - Novel remedies for neurodegenerative disease A medicament for treating neurodegenerative diseases, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from the C-terminal of selenoprotein P. An excellent medicament for treating neurodegenerative diseases, especially suitable for treating neurodegenerative diseases with ataxia as a principal symptom is ... 06/23/05 - 20050137135 - Novel analogues of glucose-dependent insulinotropic polypeptide The present invention relates to novel C-terminal truncated fragments and novel N-terminal modified analogues of gastric inhibitory polypeptide as well as various GIP analogues with a reduced peptide bond or alterations of the amino acids close to the dipeptidyl peptidase IV (DPIV)-specific cleavage site providing improved DPIV-resistance and prolonged half-life. ... 06/09/05 - 20050124546 - Oligopeptide lyophilisate, their preparation and use A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried. ... 06/09/05 - 20050124545 - Cosmetic or parmaceutical composition containing peptides A cosmetic and/or dermatological and/or pharmaceutical composition includes, as the active ingredient, at least one peptide with sequence X1-Y-Phe-Thr-X2-Ala-Thr-Z-Ile-X3-Leu-X4-Phe-Leu-X5; wherein: X1, X2, X3, X4, X5=Arg, Lys, His; Y=Asp, Glu; Z=Asn, Gln. The invention also relates to the use of said composition in order to treat, inter alia, the signs of ... 06/02/05 - 20050119185 - Synthetic hla binding peptide analogues and uses thereof The present invention provides synthetic peptides comprising at least analogues of a native peptide that specifically bind to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state, such as a cancer cell, in a mammal. Also provided are pharmaceutical compositions and immunogenic compositions comprising at ... ### FreshPatents.com Support - Terms & Conditions |